Nicho ls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. PMID: 41406444 | DOI
Linco f AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131 | DOI
Krüger N, Schneeweiss S, Desai RJ, et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Nat Med. 2025;32(1):342-352. PMID: 41207920 | DOI
Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. PMID: 39555826 | DOI
Chunduri S, Bidaoui G, Hussein MH, et al. Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients. Cardiovasc Drugs Ther. 2025;40(3):1001-1011. PMID: 40938549 | DOI
Katsura M, Horiuchi Y, Tanabe K, Wettersten N. Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults. Diabetes Obes Metab. 2026;28(6):5174-5183. PMID: 41891334 | DOI
